Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Swedish Orphan Biovitrum AB Maintains FY 2013 Financial Outlook


Thursday, 18 Jul 2013 02:00am EDT 

Swedish Orphan Biovitrum AB announced that its outlook for fiscal year 2013 remains unchanged with the total revenues for the full year 2013 expected to be in the range of between SEK 2,000 million and SEK 2,200 million. It also expects fiscal year 2013 gross margin in the range of between 57% and 59%. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2013 revenue of SEK 2,097.50 million. 

Company Quote

84.25
-0.1 -0.12%
31 Jul 2014